{
    "Clinical Trial ID": "NCT01421017",
    "Intervention": [
        "INTERVENTION 1: ",
        "  IMQ+RT",
        "  This arm has been closed as of 6/4/2014.",
        "  Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)",
        "  Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.",
        "  Week 9: response assessment",
        "  Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.",
        "  Radiation",
        "Imiquimod",
        "INTERVENTION 2: ",
        "  CTX/IMQ/RT",
        "  Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion",
        "  Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)",
        "  Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.",
        "  Week 9: response assessment",
        "  Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.",
        "  Radiation",
        "  Imiquimod",
        "Cyclophosphamide"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patients with biopsy-confirmed breast cancer.",
        "  Patients with at least measurable skin metastases and distant, measurable metastases (outside of skin) by Response Evaluation Criteria in Solid Tumors (RECIST). For patients without distant measurable metastases, an area of the skin metastases designated to not receive local therapy can be substituted. Patients with multiple (>= 2) metastatic sites (skin involvement not required), with at least one site measurable by RECIST, will be eligible for the CTX/RT cohort.",
        "  Age >= 18 years.",
        "  Eastern Cooperative Oncology Group performance status 0-2.",
        "  Patients must agree to tumor fine-needle aspiration required by protocol.",
        "  Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) can be continued if distant metastases are non-responsive (i.e. no complete response or partial response) on that regimen for >= 8 weeks as assessed by the investigator.",
        "  Patients must have adequate organ and bone marrow function as defined below:",
        "  absolute neutrophil count >= 1,300/microliter",
        "  hemoglobin >= 9.0 grams/deciliter",
        "  platelets >= 75,000/microliter",
        "  total bilirubin =< 1.5 X institutional upper limit of normal",
        "  AST (aspartate aminotransferase) =< 2.5 X institutional upper limit of normal",
        "  ALT (alanine aminotransferase) =< 2.5 X institutional upper limit of normal",
        "  creatinine =< 2 X institutional upper limit of normal if patient has chronic renal insufficiency and creatinine has been stable for > 4 months)",
        "  Informed consent.",
        "Exclusion Criteria:",
        "  Brain metastases unless resected or irradiated and stable >= 4 weeks.",
        "  Concurrent treatment with other investigational agents.",
        "  Patients who have received any local therapy (radiotherapy, high-potency corticosteroids, intralesional therapy, laser therapy or surgery) other than biopsy to the target area within 4 weeks prior to first dosing of study agent.",
        "  Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent.",
        "  Patients with an uncontrolled bleeding disorder.",
        "  Patients (with skin metastases only) who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible.",
        "  Patients with known immunodeficiency or receiving immunosuppressive therapies.",
        "  History of allergic reactions to imiquimod or its excipients.",
        "  Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements.",
        "  Pregnancy or lactation.",
        "  Women of childbearing potential not using a medically acceptable means of contraception."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Systemic Tumor Response Rates (Complete Response+Partial Response)",
        "  The systemic tumor response refers to the response at the time of best overall response. The response criteria are specially adapted from Response Evaluation Criteria in Solid Tumor for Immunotherapies (Wolchok, et al., 2009).",
        "  Time frame: 9 weeks from the start of the treatment of RT",
        "Results 1: ",
        "  Arm/Group Title: IMQ+RT",
        "  Arm/Group Description: This arm has been closed as of 6/4/2014.",
        "  Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)",
        "  Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied to all skin sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.",
        "  Week 9: response assessment",
        "  Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.",
        "  Radiation",
        "  Imiquimod",
        "  Overall Number of Participants Analyzed: 12",
        "  Measure Type: Number",
        "  Unit of Measure: proportion of tumors  .25        (.06 to .57)",
        "Results 2: ",
        "  Arm/Group Title: CTX/IMQ/RT",
        "  Arm/Group Description: Week -1 (day-7): cyclophosphamide 200mg/m2 IV as single infusion",
        "  Weeks 1-2: RT given to one metastatic skin site at 6 Gy on days 1, 3, 5, 8 and 10 (M-W-F-M-W)",
        "  Weeks 1-8: day 1-5 of each week: imiquimod 5% cream applied all sites overnight, starting on day 1 after RT, day 6-7 of each week: rest period.",
        "  Week 9: response assessment",
        "  Patients may continue to receive additional cycles (same schedule, RT given to a different site), provided that patients wish to continue, are without clinically significant progression and further treatment may be beneficial in the opinion of the investigator.",
        "  Radiation",
        "  Imiquimod",
        "  Cyclophosphamide",
        "  Overall Number of Participants Analyzed: 12",
        "  Measure Type: Number",
        "  Unit of Measure: proportion of tumors  .083        (.002 to .38)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 2/12 (16.67%)",
        "  Blurred Vision *0/12 (0.00%)",
        "  Breast Pain *1/12 (8.33%)",
        "  Fever *1/12 (8.33%)",
        "  Tumor Pain *2/12 (16.67%)",
        "  Headache *0/12 (0.00%)",
        "  Pain in extremity *0/12 (0.00%)",
        "  Breast Infection *1/12 (8.33%)",
        "  Skin Infection *1/12 (8.33%)",
        "  Neosplasms Benign *1/12 (8.33%)",
        "  Dysarthria *0/12 (0.00%)",
        "  Pleural Effusion *0/12 (0.00%)",
        "Adverse Events 2:",
        "  Total: 3/12 (25.00%)",
        "  Blurred Vision *0/12 (0.00%)",
        "  Breast Pain *0/12 (0.00%)",
        "  Fever *0/12 (0.00%)",
        "  Tumor Pain *0/12 (0.00%)",
        "  Headache *1/12 (8.33%)",
        "  Pain in extremity *1/12 (8.33%)",
        "  Breast Infection *0/12 (0.00%)",
        "  Skin Infection *1/12 (8.33%)",
        "  Neosplasms Benign *0/12 (0.00%)",
        "  Dysarthria *1/12 (8.33%)",
        "  Pleural Effusion *1/12 (8.33%)"
    ]
}